Cancer Advisor

Abstract Background: Cancer has traditionally been conceptualized as a genetic disease driven by somatic mutations. Increasing evidence, however, suggests that metabolic dysregulation—including altered mitochondrial function, glucose metabolism, and systemic hormonal signaling—plays a critical role in tumor initiation and progression. Objective: To review the current evidence supporting metabolic interventions in cancer care, including dietary strategies, repurposed drugs, nutraceuticals, and lifestyle modifications, and to evaluate their role as adjuncts to standard oncologic therapies. Methods: A narrative review was conducted synthesizing preclinical studies, observational data, and clinical trials (where available) related to metabolic approaches in oncology, including ketogenic diets, fasting protocols, insulin-modulating agents, and repurposed pharmacologic agents. Results: Metabolic interventions demonstrate heterogeneous levels of evidence. Lifestyle interventions such as p...

Abstract Lung cancer remains the leading cause of cancer mortality worldwide despite rapid progress in precision oncology and immunotherapy. The year 2025 marked a convergence of advances across molecular diagnostics, artificial intelligence–driven pathology, novel targeted and immune-based therapeutics, and increased interest in real-world drug repurposing strategies. Alongside regulatory approvals of next-generation targeted agents and bispecific immunotherapies, observational data have emerged describing the off-label use of antiparasitic agents—fenbendazole, ivermectin, and mebendazole—as adjunctive interventions in lung cancer. This integrative review synthesizes validated clinical and translational advances with mechanistic and real-world observations on repurposed anthelmintics, critically appraising their biological plausibility, evidence limitations, and implications for future research. The analysis highlights the widening gap between innovation and evidence generation, under...

Abstract Prostate cancer remains one of the most prevalent malignancies among men worldwide, with substantial heterogeneity in risk, progression, and therapeutic response. While advances in androgen receptor–targeted therapies and immunotherapy have improved outcomes in metastatic disease, overall survival gains remain modest for many patients. Concurrently, growing evidence suggests that lifestyle factors, dietary patterns, environmental exposures, and socioeconomic determinants play a critical role in disease risk and post-diagnosis survival. This review synthesizes recent evidence on prostate cancer risk factors and prevention, evaluates contemporary treatment strategies and guideline updates through 2025–2026, summarizes the evolving clinical trial landscape, and critically examines emerging case series involving repurposed antiparasitic agents such as fenbendazole and ivermectin. The convergence of population-level prevention, precision oncology, and real-world patient experimenta...

Abstract Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, characterized by aggressive biology, late diagnosis, and limited therapeutic options. Despite advances in multi-agent chemotherapy, the prognosis for metastatic disease remains poor. This review synthesizes current evidence on standard-of-care regimens, including NALIRIFOX and FOLFIRINOX, emerging targeted and immunotherapeutic approaches, and explores the potential repurposing of antiparasitic agents such as fenbendazole and ivermectin. We discuss recent clinical trials, safety profiles, and future directions for improving outcomes in stage 4 PDAC. Pancreatic Cancer Awareness Introduction Pancreatic cancer is among the most aggressive and therapeutically challenging malignancies, with a 5-year survival rate below 10% for all stages combined. Approximately 80% of pancreatic cancers are pancreatic ductal adenocarcinomas (PDAC) , which are frequently diagnosed at an advanced stage, limiting cura...